“Approximately 300,000 new patients though with no competitors in that market yet to my knowledge.”
Curium, received EMA approval several months ago. They have successfully negotiated reimbursement in 4 markets this far. My understanding is that have licensed Lantheus’s product in the EU. So telix will be second to market again. The failure of the first MA in EU was less than ideal. Better EU than US, could be worse.
“Approximately 300,000 new patients though with no competitors...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.65 |
Change
0.250(1.36%) |
Mkt cap ! $6.233B | |||
| Open | High | Low | Value | Volume |
| $18.56 | $18.81 | $18.43 | $49.28M | 2.643M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4262 | $18.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.68 | 1840 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| TLX (ASX) Chart |